A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.